Josef Schwarz - Proteome Sciences Insider

PRM -- UK Stock  

GBp 3.75  0.06  1.63%

Dr. Josef Schwarz is Head Projects Production, Proteome Sciences RD of Proteome Sciences PLC. Joseph Schwarz joined the Group in summer 2002 when Xzillion, the former proteomics division of Aventis Research and Technologies, was acquired by Proteome Sciences plc. He worked for AventisHoechst Research and Technologies for 6 years, initially as head of mass spectrometry and later as research collaboration project leader. He was instrumental in the establishment of the integrated high throughput 2DEmass spectrometry proteomics platform at the Frankfurt research facility. Josef Schwarz holds a PhD in organic chemistrymass spectrometry from the Technical University of Berlin, Germany and a MBA from the University of Durham, UK. He is an author of a number of publications and coinventor of patents.
  Executive Since 2011  MBA    
44 20 7043 2116

Management Efficiency

The company has return on total asset (ROA) of (13.16) % which means that it has lost $13.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (16.4) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 9.11 M in total debt. Proteome Sciences plc has Current Ratio of 0.3 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Found 7 records


Peter SpeirsHikma Pharmaceuticals PLC
Bryan HotstonHikma Pharmaceuticals PLC
Simon ThornRedx Pharma Plc
Tony BunnSareum Holdings plc
Paul MussendenBTG plc
Hussein ArkhaghaHikma Pharmaceuticals PLC
Bassam KanaanHikma Pharmaceuticals PLC

Entity Summary

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company was incorporated in 1993 and is headquartered in London, the United Kingdom. Proteome Sciences operates under Diagnostics Research classification in UK and traded on London Stock Exchange. It employs 34 people.Proteome Sciences plc (PRM) is traded on London Stock Exchange in UK. It is located in Hamilton House and employs 34 people.

Proteome Sciences plc Leadership Team

William Dawson, Non-Executive Director
Roger McDowell, Non-Executive Director
Christopher Pearce, Chief Executive, Executive Director
Ian Pike, COO and Executive Director
Richard Dennis, Chief Commercial Officer
Malcolm Ward, Chief Technical Officer of London Research Facility
Martin Diggle, Non-Executive Director
Jeremy Haigh, CEO, Director
Josef Schwarz, Head of Projects and Production - Proteome Sciences RandD
Ursula Ney, Non-Executive Director
Glenn Barney, VP of Bus. Devel. - USA
Gee Chee, Director of Personalised Medicine
Geoffrey Ellis, Fin. Director, Company Secretary and Executive Director

Stock Performance Indicators

Current Sentiment - PRM

Proteome Sciences plc Investor Sentiment
Macroaxis portfolio users are evenly split in their perspective on investing in Proteome Sciences plc. What is your perspective on investing in Proteome Sciences plc? Are you bullish or bearish?
50% Bullish
50% Bearish
Currently Active Assets on Macroaxis
Purchased over 500 shares of
few days ago
Traded for 6.08
Purchased over 500 shares of
few days ago
Traded for 6.08
Purchased over 100 shares of
few days ago
Traded for 2.17
Purchased over 40 shares of
few days ago
Traded for 71.99
Purchased over 300 shares of
few days ago
Traded for 9.91
Additionally take a look at Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.